Kintegral Advisory LLC Sells 314 Shares of HCA Healthcare, Inc. (NYSE:HCA)

Kintegral Advisory LLC lowered its stake in HCA Healthcare, Inc. (NYSE:HCA) by 4.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,722 shares of the company’s stock after selling 314 shares during the period. Kintegral Advisory LLC’s holdings in HCA Healthcare were worth $2,018,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. MML Investors Services LLC raised its position in shares of HCA Healthcare by 31.7% in the third quarter. MML Investors Services LLC now owns 17,816 shares of the company’s stock valued at $7,241,000 after purchasing an additional 4,285 shares during the period. Meritage Group LP bought a new position in HCA Healthcare in the 3rd quarter worth $150,548,000. Galvin Gaustad & Stein LLC bought a new stake in HCA Healthcare during the fourth quarter valued at about $18,044,000. Alpha DNA Investment Management LLC acquired a new position in shares of HCA Healthcare during the 3rd quarter worth about $869,000. Finally, NRI Wealth Management LC acquired a new stake in HCA Healthcare in the 4th quarter valued at approximately $2,896,000. 62.73% of the stock is owned by institutional investors.

HCA Healthcare Price Performance

Shares of HCA Healthcare stock opened at $316.07 on Friday. The stock has a market capitalization of $78.49 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 1.10 and a beta of 1.64. The company has a current ratio of 1.08, a quick ratio of 0.97 and a debt-to-equity ratio of 69.07. HCA Healthcare, Inc. has a 1-year low of $289.98 and a 1-year high of $417.14. The firm’s 50-day moving average price is $313.53 and its two-hundred day moving average price is $350.83.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, January 24th. The company reported $6.22 EPS for the quarter, topping analysts’ consensus estimates of $6.03 by $0.19. HCA Healthcare had a return on equity of 586.47% and a net margin of 8.16%. During the same period last year, the company earned $5.90 EPS. On average, equities analysts predict that HCA Healthcare, Inc. will post 24.98 earnings per share for the current fiscal year.

HCA Healthcare Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 17th will be paid a dividend of $0.72 per share. This is a boost from HCA Healthcare’s previous quarterly dividend of $0.66. This represents a $2.88 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, March 17th. HCA Healthcare’s dividend payout ratio is 13.11%.

Insiders Place Their Bets

In other news, SVP Jennifer Berres sold 9,533 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $322.59, for a total transaction of $3,075,250.47. Following the transaction, the senior vice president now owns 15,412 shares of the company’s stock, valued at $4,971,757.08. This represents a 38.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on HCA shares. Bank of America reduced their price objective on HCA Healthcare from $380.00 to $370.00 and set a “buy” rating for the company in a research report on Monday, January 27th. Raymond James downgraded shares of HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. KeyCorp decreased their target price on HCA Healthcare from $420.00 to $370.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley reduced their price objective on HCA Healthcare from $406.00 to $355.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Finally, TD Cowen reduced their target price on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. One analyst has rated the stock with a sell rating, three have given a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $385.67.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.